EBV Symptoms and Treatment
For acute EBV infection (infectious mononucleosis), treatment is supportive only, as antiviral therapy has minimal clinical benefit despite reducing viral shedding 1. However, chronic active EBV infection (CAEBV) requires aggressive management with hematopoietic stem cell transplantation for definitive cure.
Symptoms of EBV Infection
Acute Infectious Mononucleosis
The typical presentation includes 2, 3:
- Incubation period: Unusually long at approximately 6 weeks
- Classic triad: Fever, pharyngitis (sore throat), and lymphadenopathy
- Additional symptoms:
- Profound fatigue lasting several weeks
- Hepatosplenomegaly
- Lymphocytosis on blood work
Chronic Active EBV Infection (CAEBV)
This is a rare but severe form requiring specific diagnostic criteria 4:
Core symptoms (persistent or recurrent):
- Prolonged or intermittent fever
- Lymphadenopathy and/or hepatosplenomegaly
- Debilitating fatigue, sore throat, lymph node pain
- Headache, myalgia, arthralgia
Serious complications that distinguish CAEBV from simple mononucleosis 4:
- Hematological disorders (thrombocytopenia, hemophagocytic lymphohistiocytosis)
- Cardiovascular: coronary aneurysms, valvular disease
- Neurological, pulmonary, ocular, and dermal manifestations
- Hypersensitivity to mosquito bites (characteristic finding)
- Risk of progression to T-cell or NK-cell lymphomas
Treatment Approach
Acute Infectious Mononucleosis
Standard management is symptomatic only 5, 1:
- Rest and hydration
- Analgesics for pain/fever
- Acyclovir is NOT recommended for routine cases—clinical trials showed it inhibits viral shedding but provides minimal symptom relief 1
Specific interventions for complications 3:
Hepatitis (common, self-limiting):
- Monitor liver function tests in symptomatic cases
- No specific treatment needed
Airway compromise from tonsillar enlargement:
- Systemic corticosteroids during hospitalization
- This is the only clear indication for steroids in EBV
Splenic rupture (rare, occurs within 3 weeks of diagnosis):
- May occur spontaneously
- Restrict contact sports and heavy physical activity
- Consider ultrasound assessment of spleen size for risk stratification
- No consensus on safe return-to-activity timeline
Combined therapy consideration: One pilot study showed acyclovir plus prednisolone for 10 days in fulminant mononucleosis produced clinical improvement in 12/15 patients within 3 days 1, but this is not standard practice.
Chronic Active EBV Infection (CAEBV)
This requires aggressive management due to poor prognosis 6:
Diagnostic confirmation needed 4:
- Elevated anti-VCA IgG (≥1:640) and anti-EA IgG (≥1:160)
- EBV DNA >10^2.5 copies/mg in peripheral blood mononuclear cells
- Histopathologic grading (Grade 1-3, with Grade 3 being neoplastic)
- Identify infected cell type (T-cell vs NK-cell vs mixed)
Treatment algorithm 6:
- Initial chemotherapy: Achieves response in 64.4% overall, but only 33.3% in Grade-3 disease
- Hematopoietic stem cell transplantation (HSCT):
- Performed in 85.1% of cases
- Dramatically improves survival: 86.0% in transplanted vs 6.7% in non-transplanted patients
- Grade-1 patients have best transplant eligibility (94.3%)
- This is the definitive treatment for CAEBV
Prognosis 6:
- 3-year overall survival: 75.1% for entire cohort
- Grade-1 disease: 84.9% survival
- Grades 2-3: 63-67% survival
- Histopathologic grade is the key prognostic factor
Key Clinical Pitfalls
- Do not use acyclovir routinely for infectious mononucleosis—it doesn't improve clinical outcomes 1
- Recognize CAEBV early: Symptoms persisting >3 months warrant evaluation 3
- Monitor for late complications: Increased risk of Hodgkin lymphoma, Burkitt lymphoma, and multiple sclerosis 3, 7
- Multisite biopsies may be needed for CAEBV diagnosis, as spatial heterogeneity exists (extramedullary sites show higher-grade disease than bone marrow) 6
- T/NK-cell mixed immunophenotype is more common in higher-grade CAEBV (60% in Grade-3 vs 11.3% in Grade-1) 6